Ivonescimab
I-MAC
Dana-Farber Cancer Institute · Phase 2 · Recruiting · Enrollment 35
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
Ivonescimab
Dana-Farber Cancer Institute · Phase 2 · Recruiting · Enrollment 35
| Arm | Reported safety |
|---|
A count stays a count. This page does not turn a count into a percent.